1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

ADOPT data not major setback for Eliquis from BMS/Pfizer

 
• By Eleanor Malone

Eliquis (apixaban), Bristol-Myers Squibb/Pfizer's new oral direct Factor Xa inhibitor anticoagulant, has failed to show superiority to the standard of care low molecular weight heparin enoxaparin (Sanofi's Lovenox/Clexane) in preventing venous thromboembolism in a Phase III trial in patients with acute medical illness.

Eliquis (apixaban), Bristol-Myers Squibb/Pfizer's new oral direct Factor Xa inhibitor anticoagulant, has failed to show superiority to the standard of care low molecular weight heparin enoxaparin (Sanofi's Lovenox/Clexane) in preventing venous thromboembolism in a Phase III trial in patients with acute medical illness.

While the news is not insignificant - Jefferies analysts had predicted BMS's revenues would reach $360 million for this indication by 2016 under its 50-50 profit split with Pfizer -...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapeutic Category

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.